Once Versus Thrice Daily Colistin in Critically Ill Ptients with Multi-Drug Resistant Infections

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2017 Dec 5

PMID 29201114

Citations 4

Authors

Monireh Ghazaeian

Majid Mokhtari

Mehran Kouchek

Mirmohammad Miri

Reza Goharani

Robabeh Ghodssi-Ghassemabadi

Mohammad Sistanizad

Affiliations

Soon will be listed here.

Abstract

Conclusion: We did not find any statistically significant differences in the serum PCT levels, ICU LOS or ICU mortality, between the two groups, who received maximum recommended dose of CMS with 2 different intervals of every 8 or 24 h.

Citing Articles

Optimal dosing interval of intravenous Colistin monotherapy versus combination therapy: A systematic review and meta-analysis.

Ahmadpour F, Shaseb E, Izadpanah M, Rakhshan A, Hematian F Eur J Transl Myol. 2022; 32(4).

PMID: 36533669 PMC: 9830404. DOI: 10.4081/ejtm.2022.10833.

Antibiotics utilization patterns and dosage appropriateness among patients receiving hemodialysis.

Himali N, Al Suleimani Y, Al-Zakwani I, Abdelrahman A Saudi Pharm J. 2022; 30(7):971-978.

PMID: 35903523 PMC: 9315296. DOI: 10.1016/j.jsps.2022.05.005.

Antibiotic Prescribing Trends Before and After Implementation of an Audit and Feedback Program in Internal Ward of a Tertiary Hospital in Tehran.

GolAli E, Sistanizad M, Salamzadeh J, Haghighi M, Solooki M Iran J Pharm Res. 2020; 18(4):2136-2143.

PMID: 32184878 PMC: 7059028. DOI: 10.22037/ijpr.2019.1100833.

Interim Study: Comparison Of Safety And Efficacy of Levofloxacin Plus Colistin Regimen With Levofloxacin Plus High Dose Ampicillin/Sulbactam Infusion In Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant Acinetobacter.

Mosaed R, Haghighi M, Kouchak M, Miri M, Salarian S, Shojaei S Iran J Pharm Res. 2019; 17(Suppl2):206-213.

PMID: 31011353 PMC: 6447873.

References

Talbot G, Bradley J, Edwards Jr J, Gilbert D, Scheld M, Bartlett J . Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006; 42(5):657-68. DOI: 10.1086/499819. View

Imberti R, Cusato M, Villani P, Carnevale L, Iotti G, Langer M . Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010; 138(6):1333-9. DOI: 10.1378/chest.10-0463. View

Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I . Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009; 53(8):3430-6. PMC: 2715599. DOI: 10.1128/AAC.01361-08. View

Becker K, Nylen E, White J, Muller B, Snider Jr R . Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004; 89(4):1512-25. DOI: 10.1210/jc.2002-021444. View

Heyland D, Johnson A, Reynolds S, Muscedere J . Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med. 2011; 39(7):1792-9. DOI: 10.1097/CCM.0b013e31821201a5. View

Matthaiou D, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G . An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012; 38(6):940-9. DOI: 10.1007/s00134-012-2563-7. View

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

Daikos G, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P . Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother. 2010; 22(3):175-8. DOI: 10.1179/joc.2010.22.3.175. View

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

10.

Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I . Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003; 7(5):R78-83. PMC: 270720. DOI: 10.1186/cc2358. View

11.

Muller B, Becker K, Schachinger H, Rickenbacher P, HUBER P, Zimmerli W . Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000; 28(4):977-83. DOI: 10.1097/00003246-200004000-00011. View

12.

. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. DOI: 10.1164/rccm.200405-644ST. View

13.

von Lilienfeld-Toal M, Lehmann L, Raadts A, Hahn-Ast C, Orlopp K, Marklein G . Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol. 2009; 47(8):2405-10. PMC: 2725651. DOI: 10.1128/JCM.00491-09. View

14.

Nylen E, Muller B, Becker K, Snider R . The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003; 36(6):823-4; author reply 826-7. DOI: 10.1086/368088. View

15.

Owen R, Li J, Nation R, Spelman D . In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007; 59(3):473-7. DOI: 10.1093/jac/dkl512. View

16.

Markou N, Markantonis S, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S . Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008; 30(1):143-51. DOI: 10.1016/j.clinthera.2008.01.015. View

17.

Livermore D . Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002; 34(5):634-40. DOI: 10.1086/338782. View

18.

Harbarth S . [The effect of antimicrobial use on emergence and selection of resistance]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007; 42(2):130-5. DOI: 10.1055/s-2007-971165. View

19.

Dalfino L, Puntillo F, Mosca A, Monno R, Spada M, Coppolecchia S . High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012; 54(12):1720-6. PMC: 3357480. DOI: 10.1093/cid/cis286. View

20.

Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C . Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007; 131(1):9-19. DOI: 10.1378/chest.06-1500. View